Author

A. U. Kabir

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Research Focus:gene regulatory network inference· 2 Organism:human· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1

Frequent Co-Authors

K. CHOI· 3 shared K. KRCHMA· 3 shared M. SUBRAMANIAN· 3 shared J. WU· 2 shared M. KIM· 2 shared B. Zinselmeyer· 1 shared C. M. HALABI· 1 shared C. Stewart· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

K. CHOI

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivPreprintMar 2, 2023

Zbtb46 coordinates angiogenesis and immunity to control tumor outcome

A. U. KABIR, M. SUBRAMANIAN, M. KIM…·K. CHOI

This study identifies Zbtb46 as a regulator that coordinates angiogenesis and immunity in tumors, with its downregulation promoting a pro-tumor microenvironment and its restoration improving tumor outcomes.

DOI 10.1101/2023.03.02.530835

mousebulk RNA-seq

𝕏 PostBluesky

ImmunologybioRxivPreprintJul 7, 2022

Interleukin-1α and Leukemia Inhibitory Factor Promote Extramedullary Hematopoiesis

D. Barisas, M. Kim, M. Subramanian…·K. Choi

This study identifies IL-1 and LIF as factors promoting EMH by activating splenic niche cells and inducing an inflammatory gene signature in HSPCs.

DOI 10.1101/2022.07.07.499256

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivDec 23, 2021

Conserved angio-immune subtypes of the cancer microenvironment predict response to immune checkpoint blockade therapy

M. Subramanian, A. U. Kabir, D. A. G. Barisas…·K. Choi

The paper identifies three conserved angio-immune subtypes in cancer microenvironments and shows that high immune activity with low angiogenesis correlates with better response to immune checkpoint blockade therapy.

DOI 10.1016/j.xcrm.2022.100896

humanbulk RNA-seq

𝕏 PostBluesky